Hologic INC Form 4 insider transactions

Hologic CEO Stephen P. MacMillan had 6,874 shares withheld at $74.15 to cover taxes on vested RSUs, and now reports 1,423,837 direct and 1,146,829 indirect shares.

Hologic’s International Group President Jan Verstreken had 196 shares withheld at $74.15 to cover taxes on vested RSUs, retaining 134,039 shares post-transaction.

Hologic’s GYN Surgical President Brandon Schnittker withheld 178 shares at $74.15 to cover taxes on RSU vesting, leaving 17,602 shares owned directly.

Hologic’s Diagnostic Solutions President Jennifer M. Schneiders withheld 561 shares to cover taxes on vested RSUs, leaving 41,318 shares owned directly.

Hologic's Chief Financial Officer, Karleen Marie Oberton, disposed of 1,333 shares of common stock to cover tax obligations related to restricted stock unit vesting.

Hologic's Chief Operating Officer, Essex D. Mitchell, disposed of 1,342 shares of common stock to cover tax obligations related to restricted unit vesting.

Hologic's General Counsel, Anne M. Liddy, disposed of 337 shares of common stock to cover tax obligations related to vested restricted stock units.

Hologic's Principal Accounting Officer, Benjamin Jordan Cohn, disposed of 187 shares of common stock to cover tax obligations related to vested restricted stock units.

Hologic's Chairman, President, and CEO, Stephen P. MacMillan, reported recent transactions involving the company's common stock, including tax-related dispositions and the grant of restricted stock units.

Hologic's Principal Accounting Officer, Benjamin Jordan Cohn, reported recent acquisitions of restricted stock units and dispositions for tax obligations.

Hologic's Group President, International, Jan Verstreken, reported recent stock transactions including RSU grants and tax-related share disposals.

Hologic's President of GYN Surgical, Brandon Schnittker, reported an acquisition of 12,113 restricted stock units and related tax-driven dispositions of common stock.

Hologic's President of Diagnostic Solutions, Jennifer M. Schneiders, reported recent stock transactions including the acquisition of restricted stock units and shares withheld for tax obligations.

Hologic's Chief Financial Officer, Karleen Oberton, reported recent equity transactions including RSU grants and tax-related share dispositions.

Hologic's Chief Operating Officer, Essex D. Mitchell, reported the acquisition of 47,106 restricted stock units and the disposition of 5,628 shares for tax obligations.

Hologic Inc.'s President of Breast & Skeletal, Mark W. Horvath, was granted 13,458 restricted stock units vesting over three years.

Hologic's General Counsel, Anne M. Liddy, reported recent stock transactions including RSU grants and tax-related share disposals.

Hologic Inc.'s Chairman, President, and CEO, Stephen P. MacMillan, is set to acquire 83,589 shares of common stock through performance stock units on November 4, 2025.

Hologic's Group President, International, Jan Verstreken, acquired 15,196 shares of common stock through the vesting of performance stock units.

Hologic's Chief Financial Officer, Karleen Marie Oberton, reported the acquisition of 17,095 shares of common stock through performance stock units.

Hologic's Chief Operating Officer, Essex D. Mitchell, increased his beneficial ownership by 9,116 shares of common stock through the vesting of performance stock units.

Hologic's President of Breast & Skeletal, Mark W. Horvath, acquired 2,278 shares of common stock through performance unit vesting.

Hologic's Principal Accounting Officer, Benjamin Jordan Cohn, acquired 2,656 shares of common stock through performance stock units, increasing his total beneficial ownership.

Hologic Director Christiana Stamoulis exercised and immediately sold 7,402 shares of common stock under a pre-arranged 10b5-1 trading plan.

Hologic's Chairman, President, and CEO, Stephen P. MacMillan, exercised stock options and subsequently sold 138,358 shares of common stock under a pre-arranged 10b5-1 trading plan.

Hologic Inc. (HOLX) Division President, Brandon Schnittker, reported the disposition of 69 shares of common stock, valued at $62.17 per share, to cover tax obligations arising from the vesting of restricted stock units.

Director Martin D. Madaus purchased 5,445 shares of Hologic Inc. common stock at an average price of $55.236 on May 7, 2025.

Director Wayde D. McMillan reports acquisition of restricted stock units and stock options in Hologic Inc.

Director Amy McBride Wendell reports acquisition of common stock and stock options in Hologic Inc.

Director Stacey D. Stewart reports acquisition of common stock and stock options in Hologic Inc.